Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Larimar Therapeutics (LRMR) to $18 from $22 and keeps an Outperform rating on the shares. Larimar will have new open-label data for nomlabofusp in September, which should provide more confidence in the Friedreich’s ataxia candidate, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics
- Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses
- Promising Data and Optimistic Outlook Drive Buy Rating for Larimar Therapeutics
- Larimar Therapeutics Reports Q2 2025 Financial Results
- Larimar Therapeutics reports Q2 EPS (41c), consensus (49c)